Effect of Steroid Injections in a Knee With Osteoarthritis
Primary Purpose
Osteoarthritis (OA) of the Knee
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Triamcinolone Acetonide
0.9% Sodium Chloride Injection as Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis (OA) of the Knee focused on measuring OA, Knee arthritis, MRI, Steroid
Eligibility Criteria
Inclusion Criteria:
- Female or Male, Age ≥ 45 years
- Chronic knee discomfort based on affirmative response to the question "During the past 12 months, have you had any pain, aching, or stiffness in or around your knee(s) on most days for at least one month?"
- Baseline (Month 0) Pain score >2 on at least one of the WOMAC weight-bearing pain questions; and total weight-bearing pain score <8
- Tibiofemoral or patellofemoral OA on posterior-anterior weight-bearing semi-flexed or lateral knee radiographs with severity equivalent to Kellgren and Lawrence grade 2 or 3
- Evidence of synovitis on ultrasound at screening
- Clinical examination confirming knee pain or discomfort referable to the knee joint
- Prepared to discontinue NSAID(s)/analgesic(s) for 2 days prior to each assessment
Exclusion Criteria:
- Prior septic (study) knee joint
- Prior reconstructive surgery in the study knee
- Prior osteonecrosis (avascular necrosis of bone)
- Chronic use of oral corticosteroids; knee intra-articular corticosteroid injection within 3 months of Month 0 (baseline) visit
- Ongoing use of doxycycline, indomethacin, glucosamine and/or chondroitin; or use of these within 2 months of Screening visit
- Evidence of other inflammatory joint disease (e.g., gout, CPPD)
- Serious medical conditions or impairments that, in the view of the investigator, would obstruct their participation in the trial such as uncontrolled diabetes, uncontrolled hypertension, opiate dependency
- Plan to permanently relocate from the region, or take an extended vacation for greater than 3 months during the trial period
- Planned arthroscopy and/or arthroplasty in the study knee.
- Any contra-indication to having an MRI
- Inability to speak or comprehend English
Sites / Locations
- Tufts Medical Center / Division of Rheumatology
- Tufts Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Triamcinolone Acetonide
Sodium Chloride
Arm Description
40 mg into the study knee joint every 12 weeks for a total of 8 injections.
0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
Outcomes
Primary Outcome Measures
Change in Mean Cartilage Thickness in the Index Compartment (Compartment With the Most Damage)
Mean cartilage thickness was measured on knee MRI (Philips Achieva X-Series 3.0 Tesla scanner). Missing data were imputed.
Change in Knee Pain Severity During the Past 48 Hours From the WOMAC LK3.1 Pain Score Questionnaire.
Pain subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Pain subscale score was used for this outcome measure. The Pain subscale consists of five items, each ranging from 0 to 4, making the total Pain subscore 0 to 20. Higher scores represent higher levels of pain, whereas lower scores represent lower levels of pain.
Missing data were imputed.
Secondary Outcome Measures
Change in Volume of Peri-articular Bone Marrow Lesions Measured on Knee MRI.
Change in volume of peri-articular bone marrow lesions measured on knee MRI on the log scale. Missing data were imputed.
Change in Effusion Volume Measured on Knee MRI.
Change in effusion volume measured on knee MRI on the log scale. Missing data were imputed.
Change in Area of Denudation Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
Change in area of denudation measured on knee MRI in the index compartment (compartment with the most damage). Missing data were imputed.
Change in Volumetric Cartilage Damage Index (CDI) Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
Change in volumetric cartilage damage index (CDI) measured on knee MRI in the index compartment (compartment with the most damage). Missing data were imputed.
Change in Function Severity During the Past 48 Hours From the WOMAC LK3.1 Function Score Questionnaire.
Physical Function subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Physical Function subscale score was used for this outcome measure. The Physical Function subscale consists of 17 items, each ranging from 0 to 4, making the total Function subscore 0 to 68. Higher scores represent higher levels of difficulty performing daily activities, whereas lower scores represent lower levels of difficulty performing daily activities.
Missing data were imputed.
Change in Knee Stiffness During the Past 48 Hours From the WOMAC LK3.1 Stiffness Score Questionnaire.
Stiffness subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Stiffness subscale score was used for this outcome measure. The Stiffness subscale consists of two items, each ranging from 0 to 4, making the total Stiffness subscore 0 to 8. Higher scores represent higher levels of stiffness, whereas lower scores represent lower levels of stiffness.
Missing data were imputed.
Change in Patient's Global Assessment (Visual Analogue Scale).
The response to the question, "Considering all the ways your knee affects you, how much pain are you having today?", was measured and the change in the scoring was evaluated. The Patient's Global Assessment (PGA) is measured on a scale of 0 to 100 millimeters. Higher scores represent a higher level of disease activity or a worse global health. Missing data were imputed.
Change in Time to Complete a Twenty-meter Walk.
Change in time (seconds) to complete a twenty-meter walk. Missing data were imputed.
Change in Time to Complete 5 Chair Stands.
Change in time (seconds) to complete 5 chair stands. Missing data were imputed.
Full Information
NCT ID
NCT01230424
First Posted
October 27, 2010
Last Updated
June 30, 2017
Sponsor
Tufts Medical Center
Collaborators
Boston University
1. Study Identification
Unique Protocol Identification Number
NCT01230424
Brief Title
Effect of Steroid Injections in a Knee With Osteoarthritis
Official Title
Effect of Intra-articular Steroids on Structural Progression of Knee OA: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tufts Medical Center
Collaborators
Boston University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A steroid (triamcinolone) 40 mg will be compared to placebo in a randomized placebo-controlled clinical trial testing the effect of this steroid versus placebo given into the study knee joint that has osteoarthritis (OA). The knee injection will be given once every 12 weeks over two years for a total of eight knee injections. How well each participant tolerates each injection and all the injections over time will be assessed. The safety of getting a knee injection every 12 weeks will be assessed by collecting reported adverse effects, knee examinations, and clinical laboratory tests. Participants will complete questionnaires, X-ray, MRIs, and bone density tests as part of this study.
Detailed Description
This study was a two-year stratified and block-randomized double-blind, placebo controlled clinical trial of the effect of intra-articular triamcinolone 40 mg injectable suspension, administered every 3 months over two years (for a total of 8 doses). The randomization was stratified by the baseline radiographic severity of knee OA (Kellgren and Lawrence grade of 2 or 3) and gender. An interim analysis would have been conducted after the first half of participants has completed the trial. This interim analysis would have allowed the trial to be stopped early for either success or futility, or allow the trial to continue if neither success nor futility has been established. However, the plan for interim analysis was eliminated with the support of the DSMB because of feasibility issues for completing cartilage measurements contemporaneously and because early trial cessation would preclude analysis of informative secondary outcomes. The primary structural outcome objective in this study was cartilage volume loss; secondary structural outcomes included peri-articular bone marrow lesions (BML), tibial peri-articular bone density ratio (paBMD). The primary clinical outcome objective was the pain domain of the WOMAC© LK3.1; secondary clinical outcomes included WOMAC© LK3.1 stiffness and function scores and physical function tests.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis (OA) of the Knee
Keywords
OA, Knee arthritis, MRI, Steroid
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
140 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Triamcinolone Acetonide
Arm Type
Experimental
Arm Description
40 mg into the study knee joint every 12 weeks for a total of 8 injections.
Arm Title
Sodium Chloride
Arm Type
Placebo Comparator
Arm Description
0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
Intervention Type
Drug
Intervention Name(s)
Triamcinolone Acetonide
Other Intervention Name(s)
Kenalog
Intervention Description
40 mg into the study knee joint every 12 weeks for a total of 8 injections.
Intervention Type
Drug
Intervention Name(s)
0.9% Sodium Chloride Injection as Placebo
Other Intervention Name(s)
Normal Saline for injection
Intervention Description
Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
Primary Outcome Measure Information:
Title
Change in Mean Cartilage Thickness in the Index Compartment (Compartment With the Most Damage)
Description
Mean cartilage thickness was measured on knee MRI (Philips Achieva X-Series 3.0 Tesla scanner). Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Knee Pain Severity During the Past 48 Hours From the WOMAC LK3.1 Pain Score Questionnaire.
Description
Pain subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Pain subscale score was used for this outcome measure. The Pain subscale consists of five items, each ranging from 0 to 4, making the total Pain subscore 0 to 20. Higher scores represent higher levels of pain, whereas lower scores represent lower levels of pain.
Missing data were imputed.
Time Frame
Baseline to 2 years
Secondary Outcome Measure Information:
Title
Change in Volume of Peri-articular Bone Marrow Lesions Measured on Knee MRI.
Description
Change in volume of peri-articular bone marrow lesions measured on knee MRI on the log scale. Missing data were imputed.
Time Frame
Baseline to 2 years.
Title
Change in Effusion Volume Measured on Knee MRI.
Description
Change in effusion volume measured on knee MRI on the log scale. Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Area of Denudation Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
Description
Change in area of denudation measured on knee MRI in the index compartment (compartment with the most damage). Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Volumetric Cartilage Damage Index (CDI) Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
Description
Change in volumetric cartilage damage index (CDI) measured on knee MRI in the index compartment (compartment with the most damage). Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Function Severity During the Past 48 Hours From the WOMAC LK3.1 Function Score Questionnaire.
Description
Physical Function subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Physical Function subscale score was used for this outcome measure. The Physical Function subscale consists of 17 items, each ranging from 0 to 4, making the total Function subscore 0 to 68. Higher scores represent higher levels of difficulty performing daily activities, whereas lower scores represent lower levels of difficulty performing daily activities.
Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Knee Stiffness During the Past 48 Hours From the WOMAC LK3.1 Stiffness Score Questionnaire.
Description
Stiffness subscale score was calculated from patient's responses on the Western Ontario and McMaster Universities Osteoarthritis Index Likert-type 3.1 Questionnaire. The questionnaire includes 24 items divided into 3 subscales, Pain, Stiffness, Physical Function. Only the Stiffness subscale score was used for this outcome measure. The Stiffness subscale consists of two items, each ranging from 0 to 4, making the total Stiffness subscore 0 to 8. Higher scores represent higher levels of stiffness, whereas lower scores represent lower levels of stiffness.
Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Patient's Global Assessment (Visual Analogue Scale).
Description
The response to the question, "Considering all the ways your knee affects you, how much pain are you having today?", was measured and the change in the scoring was evaluated. The Patient's Global Assessment (PGA) is measured on a scale of 0 to 100 millimeters. Higher scores represent a higher level of disease activity or a worse global health. Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Time to Complete a Twenty-meter Walk.
Description
Change in time (seconds) to complete a twenty-meter walk. Missing data were imputed.
Time Frame
Baseline to 2 years
Title
Change in Time to Complete 5 Chair Stands.
Description
Change in time (seconds) to complete 5 chair stands. Missing data were imputed.
Time Frame
Baseline to 2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female or Male, Age ≥ 45 years
Chronic knee discomfort based on affirmative response to the question "During the past 12 months, have you had any pain, aching, or stiffness in or around your knee(s) on most days for at least one month?"
Baseline (Month 0) Pain score >2 on at least one of the WOMAC weight-bearing pain questions; and total weight-bearing pain score <8
Tibiofemoral or patellofemoral OA on posterior-anterior weight-bearing semi-flexed or lateral knee radiographs with severity equivalent to Kellgren and Lawrence grade 2 or 3
Evidence of synovitis on ultrasound at screening
Clinical examination confirming knee pain or discomfort referable to the knee joint
Prepared to discontinue NSAID(s)/analgesic(s) for 2 days prior to each assessment
Exclusion Criteria:
Prior septic (study) knee joint
Prior reconstructive surgery in the study knee
Prior osteonecrosis (avascular necrosis of bone)
Chronic use of oral corticosteroids; knee intra-articular corticosteroid injection within 3 months of Month 0 (baseline) visit
Ongoing use of doxycycline, indomethacin, glucosamine and/or chondroitin; or use of these within 2 months of Screening visit
Evidence of other inflammatory joint disease (e.g., gout, CPPD)
Serious medical conditions or impairments that, in the view of the investigator, would obstruct their participation in the trial such as uncontrolled diabetes, uncontrolled hypertension, opiate dependency
Plan to permanently relocate from the region, or take an extended vacation for greater than 3 months during the trial period
Planned arthroscopy and/or arthroplasty in the study knee.
Any contra-indication to having an MRI
Inability to speak or comprehend English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy E. McAlindon, MD, MPH
Organizational Affiliation
Tufts Medical Center / Division of Rheumatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tufts Medical Center / Division of Rheumatology
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
Tufts Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28510679
Citation
McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, Ward RJ. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017 May 16;317(19):1967-1975. doi: 10.1001/jama.2017.5283.
Results Reference
derived
Links:
URL
https://www.tuftsmedicalcenter.org/ClinicalTrials/OA-9417
Description
Tufts Medical Center Rheumatology Clinical Trials
Learn more about this trial
Effect of Steroid Injections in a Knee With Osteoarthritis
We'll reach out to this number within 24 hrs